Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.76
SVA's Cash to Debt is ranked higher than
64% of the 919 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. SVA: 1.76 )
SVA' s 10-Year Cash to Debt Range
Min: 0.48   Max: No Debt
Current: 1.76

Equity to Asset 0.54
SVA's Equity to Asset is ranked higher than
66% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. SVA: 0.54 )
SVA' s 10-Year Equity to Asset Range
Min: 0.41   Max: 0.64
Current: 0.54

0.41
0.64
Interest Coverage 2.89
SVA's Interest Coverage is ranked lower than
51% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SVA: 2.89 )
SVA' s 10-Year Interest Coverage Range
Min: 1.38   Max: 9999.99
Current: 2.89

1.38
9999.99
F-Score: 6
Z-Score: 2.31
M-Score: 0.94
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 9.16
SVA's Operating margin (%) is ranked higher than
87% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. SVA: 9.16 )
SVA' s 10-Year Operating margin (%) Range
Min: -35600   Max: 50.06
Current: 9.16

-35600
50.06
Net-margin (%) 8.33
SVA's Net-margin (%) is ranked higher than
87% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -69.75 vs. SVA: 8.33 )
SVA' s 10-Year Net-margin (%) Range
Min: -39700   Max: 23.7
Current: 8.33

-39700
23.7
ROE (%) 4.74
SVA's ROE (%) is ranked higher than
85% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -28.10 vs. SVA: 4.74 )
SVA' s 10-Year ROE (%) Range
Min: -50.22   Max: 33.16
Current: 4.74

-50.22
33.16
ROA (%) 2.54
SVA's ROA (%) is ranked higher than
86% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. SVA: 2.54 )
SVA' s 10-Year ROA (%) Range
Min: -310.16   Max: 17.45
Current: 2.54

-310.16
17.45
ROC (Joel Greenblatt) (%) 6.78
SVA's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. SVA: 6.78 )
SVA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1736.59   Max: 137.22
Current: 6.78

-1736.59
137.22
Revenue Growth (%) 27.30
SVA's Revenue Growth (%) is ranked higher than
92% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. SVA: 27.30 )
SVA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 81.7
Current: 27.3

0
81.7
» SVA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

SVA Guru Trades in Q3 2013

Jim Simons 896,600 sh (+127.79%)
Chris Davis 1,473,343 sh (-43.92%)
» More
Q4 2013

SVA Guru Trades in Q4 2013

Jim Simons 1,054,996 sh (+17.67%)
Chris Davis 1,178,606 sh (-20%)
» More
Q1 2014

SVA Guru Trades in Q1 2014

Chris Davis 1,244,206 sh (+5.57%)
Jim Simons 1,031,711 sh (-2.21%)
» More
Q2 2014

SVA Guru Trades in Q2 2014

Jim Simons 1,175,000 sh (+13.89%)
Chris Davis 1,250,546 sh (+0.51%)
» More
» Details

Insider Trades

Latest Guru Trades with SVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 46.30
SVA's P/E(ttm) is ranked higher than
90% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SVA: 46.30 )
SVA' s 10-Year P/E(ttm) Range
Min: 5.44   Max: 161.43
Current: 46.3

5.44
161.43
P/B 2.15
SVA's P/B is ranked higher than
89% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 5.71 vs. SVA: 2.15 )
SVA' s 10-Year P/B Range
Min: 0.73   Max: 11.83
Current: 2.15

0.73
11.83
P/S 3.79
SVA's P/S is ranked higher than
89% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 20.23 vs. SVA: 3.79 )
SVA' s 10-Year P/S Range
Min: 0.98   Max: 26.4
Current: 3.79

0.98
26.4
EV-to-EBIT 36.17
SVA's EV-to-EBIT is ranked higher than
89% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SVA: 36.17 )
SVA' s 10-Year EV-to-EBIT Range
Min: 1.9   Max: 47.1
Current: 36.17

1.9
47.1
Shiller P/E 122.58
SVA's Shiller P/E is ranked higher than
93% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SVA: 122.58 )
SVA' s 10-Year Shiller P/E Range
Min: 15.09   Max: 182
Current: 122.58

15.09
182
Current Ratio 2.28
SVA's Current Ratio is ranked higher than
63% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. SVA: 2.28 )
SVA' s 10-Year Current Ratio Range
Min: 1.16   Max: 6.15
Current: 2.28

1.16
6.15
Quick Ratio 1.98
SVA's Quick Ratio is ranked higher than
64% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. SVA: 1.98 )
SVA' s 10-Year Quick Ratio Range
Min: 0.85   Max: 5.43
Current: 1.98

0.85
5.43

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 13.36
SVA's Price/Net Current Asset Value is ranked higher than
81% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 52.38 vs. SVA: 13.36 )
SVA' s 10-Year Price/Net Current Asset Value Range
Min: 3.37   Max: 109
Current: 13.36

3.37
109
Price/Tangible Book 2.16
SVA's Price/Tangible Book is ranked higher than
92% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. SVA: 2.16 )
SVA' s 10-Year Price/Tangible Book Range
Min: 0.9   Max: 14.04
Current: 2.16

0.9
14.04
Price/DCF (Projected) 6.09
SVA's Price/DCF (Projected) is ranked higher than
92% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SVA: 6.09 )
SVA' s 10-Year Price/DCF (Projected) Range
Min: 1.03   Max: 22.73
Current: 6.09

1.03
22.73
Price/Median PS Value 0.79
SVA's Price/Median PS Value is ranked higher than
89% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. SVA: 0.79 )
SVA' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 3.94
Current: 0.79

0.26
3.94
Price/Graham Number 1.69
SVA's Price/Graham Number is ranked higher than
96% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SVA: 1.69 )
SVA' s 10-Year Price/Graham Number Range
Min: 0.5   Max: 3.89
Current: 1.69

0.5
3.89
Earnings Yield (Greenblatt) 2.80
SVA's Earnings Yield (Greenblatt) is ranked higher than
67% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. SVA: 2.80 )
SVA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 52.8
Current: 2.8

2.1
52.8
Forward Rate of Return (Yacktman) 1.42
SVA's Forward Rate of Return (Yacktman) is ranked higher than
89% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: -10.76 vs. SVA: 1.42 )
SVA' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.3   Max: 7.9
Current: 1.42

-7.3
7.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SVQ.Germany
Sinovac Biotech Ltd. formerly known as Net-Force System Inc. was incorporated in Antigua and Barbuda on March 1, 1999. It is a holding company and conducts its business in China through its 73.09% majority-owned subsidiary, Sinovac Beijing, and its wholly owned subsidiaries, Tangshan Yian, Sinovac Biological, Sinovac Hong Kong and 30%-owned joint venture Sinovac Dalian. It is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Its portfolio of regulatory approved products consists of vaccines against the hepatitis A, hepatitis B and influenza viruses. In 2002, the Company launched its first product, Healive, which was the first inactivated hepatitis A vaccine developed, produced and marketed in China. It is administered intramuscularly and is available in a 1.0 ml dose for adults and a 0.5 ml dose for children. In 2005, the Company received regulatory approvals in China for the production of Bilive, which is a combined vaccine formulated by purified inactivated hepatitis A virus antigen, available from Healive, and the recombinant yeast-derived hepatitis B surface antigen. Bilive is used to prevent infection from hepatitis A and hepatitis B. Bilive is available in different doses for use in both adults and children. The 1.0ml dose is for non-immune adults and adolescents 16 years of age and older. The Company's Anflu vaccine is an inactivated split influenza vaccine formulated from three split inactivated virus solutions. Anflu is standardized annually according to the virus strains recommended by WHO for the current year. In April 2008, the Company was granted a production license for Panflu by the China State Food and Drug Administration (SFDA). Panflu is the first and only approved vaccine available in China against the H5N1 influenza virus. Under the production license for Panflu granted by SFDA, the vaccine is solely approved for supply to the Chinese national vaccine stockpiling program and would not be sold directly to the commercial market. The Company's pipeline consists of vaccine candidates in the pre-clinical and clinical development phases in China, including human vaccines for the EV71, Japanese encephalitis and rabies currently in pre-clinical development, a vaccine for the SARS virus that has completed a Phase I clinical trial and a split viron vaccine for the H5N1 influenza virus that has completed a Phase II clinical trial. Its pipeline also includes a vaccine for rabies in animals that is currently in field trials. Its competitors include large pharmaceutical, biotechnology companies and academic research institutions, both domestic and international.The Company is subject to PRC laws and regulations governing the use, manufacture, storage, handling or disposal of hazardous materials and waste products.
» More Articles for NAS:SVA

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Sinovac Announces New Presentation Time for Aegis Healthcare & Technology Conference Sep 05 2014
Sinovac to Participate in Upcoming Investor Conferences Sep 02 2014
Sinovac Announces Results of 2014 Annual General Meeting of Shareholders Aug 27 2014
Sinovac Reports Unaudited Second Quarter Financial Results Aug 14 2014
Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results Jul 25 2014
Sinovac Receives Beijing CDC Tender to Supply Seasonal Flu Vaccine Anflu Jul 23 2014
Sinovac Biotech receives tender to supply Healive in Beijing under EPI Jul 21 2014
Sinovac Receives Tender to Supply Inactivated Hepatitis A Vaccine Healive in Beijing Under Expanded... Jul 21 2014
Sinovac Schedules 2014 Annual Meeting of Shareholders Jul 14 2014
Sinovac Announces Favorable Reduction in Value Added Tax Rate Jun 25 2014
Sinovac Biotech's (SVA) CEO Weidong Yin on Q1 2014 Results - Earnings Call Transcript May 22 2014
Sinovac Biotech reports Q1 EPS 0c, consensus (3c) May 21 2014
Sinovac Reports Unaudited First Quarter 2014 Financial Results May 21 2014
Sinovac to Host Conference Call to Report First Quarter 2014 Unaudited Financial Results May 12 2014
Sinovac Biotech enters technology transfer agreement with Intravacc Apr 28 2014
Sinovac Enters Technology Transfer Agreement with Intravacc to Develop and Commercialize Sabin... Apr 28 2014
Sinovac Receives Notification of China Government Grant for EV71 Vaccine Project Apr 24 2014
SINOVAC BIOTECH LTD Financials Apr 22 2014
Sinovac Files 2013 Annual Report on Form 20-F Apr 16 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK